Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBF-RIC in Myeloid Malignancies >=55 Years
NCT05436561Phase 2Recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Jun 2022
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine, busulfan and melphalan in Myeloid malignancy, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and 1 more, sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Disease-free survival at 2 years. Started Jun 2022; status: recruiting.
02
Drugs
fludarabinebusulfanmelphalan
03
Conditions
Myeloid malignancyacute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT05436561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05436561.